AbClon, founded in 2010, is a pioneering company in the Biotechnology and Health Care sectors. Specializing in antibody therapeutics and cell therapy, AbClon is dedicated to addressing intractable diseases, with a mission of advancing global health and hope.
The company's slogan, "AbClon pioneers antibody therapeutics and cell therapy for intractable diseases, advancing global health and hope.", captures its commitment to innovation and impact in the medical field. Operating at the intersection of Health and Wellness and Information Technology, AbClon represents a significant player in the industry's cutting-edge therapies.
In its recent funding round on 27 July 2022, AbClon secured a KRW22.00B Convertible Note investment. This investment was led by key players including Shinhan Capital, Quad Asset Management, and FOCUS ASSET MANAGEMENT, indicating strong confidence in the company's future prospects. With their strategic backing, AbClon is well-positioned to continue its innovative work in transforming healthcare solutions.
